Rapport's RAP-219 Shows Sustained Seizure Reduction Beyond Treatment Period

Rapport Therapeutics said its investigational therapy RAP-219 delivered a 90% median reduction in seizures during the first four weeks after dosing ended, indicating durable clinical benefit. The update is positive for the company’s development program and supports the drug’s efficacy profile, though it remains early-stage and is unlikely to have broad market impact.

Analysis

Rapport Therapeutics said its investigational therapy RAP-219 delivered a 90% median reduction in seizures during the first four weeks after dosing ended, indicating durable clinical benefit. The update is positive for the company’s development program and supports the drug’s efficacy profile, though it remains early-stage and is unlikely to have broad market impact.